Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Annaly Capital Management, Inc. (NLY) Price & Performance

Eli Lilly And CoTrade
Annaly Capital Management, Inc.Trade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Annaly Capital Management, Inc. — how do they compare? Eli Lilly And Co trades at $1,222.3 (market cap $1.08T), while Annaly Capital Management, Inc. trades at $23.33 (market cap $17.44B). The key difference: Eli Lilly And Co is far larger — about 61.9× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (12.96%). Which is the better fit depends on your goals.

LLYNLY
Market Cap
$1.08T$17.44B
Sector
HealthFinancials
52-Week High
$1.24K$24.40
52-Week Low
$639.43$20.21
Enterprise Value
$1.13T
Dividend Yield
0.57%12.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Annaly Capital Management, Inc.

NLY trades at $23.28, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.59 and a high ROE of 20.66%. Recent quarterly earnings have consistently beaten estimates, and the company maintains a significant dividend yield. Analyst consensus is positive, with a $24.50 price target, supported by recent upgrades and institutional buying activity.

The outlook for NLY is favorable, driven by earnings growth and a high dividend yield, but risks include interest rate sensitivity and high leverage. The stock offers value and income appeal, yet investors should weigh the cyclical nature of the mortgage REIT sector against the strong analyst support and recent financial performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Annaly Capital Management, Inc.

Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.

Read more on NLY